HomeVoclosporin

Voclosporin

Also known as: Lupkynis

Calcineurin Inhibitor ImmunosuppressantCalcineurin InhibitorsP-Glycoprotein Inhibitors

Route: Oral

Check Voclosporin Interactions →
12 interactions on record⛔ Black Box Warning

Voclosporin has 12 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Clarithromycin, Itraconazole, Ketoconazole. Patients taking Voclosporin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
12
Contraindicated
3
Major
6
Moderate
3

Contraindicated (3)

  • Voclosporin + ClarithromycinCo-administration of LUPKYNIS with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) is contra
  • Voclosporin + ItraconazoleCo-administration of LUPKYNIS with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) is contra
  • Voclosporin + KetoconazoleCo-administration of LUPKYNIS with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) is contra

Major (6)

  • Voclosporin + AtorvastatinOATP1B1/OATP1B3 substrate; voclosporin increases exposure. Monitor for myopathy and rhabdomyolysis; reduce dosage as rec
  • Voclosporin + FluvastatinOATP1B1/OATP1B3 substrate; voclosporin increases exposure. Monitor for myopathy and rhabdomyolysis; reduce dosage as rec
  • Voclosporin + PitavastatinOATP1B1/OATP1B3 substrate; voclosporin increases exposure. Monitor for myopathy and rhabdomyolysis; reduce dosage as rec
  • Voclosporin + PravastatinOATP1B1/OATP1B3 substrate; voclosporin increases exposure. Monitor for myopathy and rhabdomyolysis; reduce dosage as rec
  • Voclosporin + RosuvastatinOATP1B1/OATP1B3 substrate; voclosporin increases exposure. Monitor for myopathy and rhabdomyolysis; reduce dosage as rec
  • Voclosporin + SimvastatinOATP1B1 substrate; voclosporin increases simvastatin acid exposure 3.1-fold (Cmax) and 1.8-fold (AUC). Monitor for myopa

Moderate (3)

  • Voclosporin + DiltiazemModerate CYP3A4 inhibitor that increases voclosporin exposure; dosage reduction of voclosporin required.
  • Voclosporin + FluconazoleReduce LUPKYNIS dosage when co-administered with moderate CYP3A4 inhibitors (e.g., verapamil, fluconazole, diltiazem) [s
  • Voclosporin + VerapamilModerate CYP3A4 inhibitor that increases voclosporin exposure; dosage reduction of voclosporin required.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.